Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus

Abstract

Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis, recognized as an inflammatory disease of the vessel wall, probably accelerated by diabetes mellitus (DM). Elevated interleukin (IL)-6 levels have been associated with increased cardiovascular morbidity and a common polymorphism has been identified in the promoter region of the IL-6 gene. The aim of this prospective study was to investigate inflammatory mediators in PAD patients (±DM) and to investigate a possible relationship to the IL-6 gene polymorphism. Five groups of patients (DM, intermittent claudication ±DM, critical limb ischemia (CLI) ±DM) and a control group of 20 individuals each were included. Hemoglobin, high sensitive C-reactive protein (hsCRP), creatinine, blood lipids, white blood cells (WBC); CD11b/CD18; vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1), sE-selectin, sP-selectin; IL-6, IL-8, tumour necrosis factor (TNF)α, sTNFα-R1 and sTNFα-R2 were analysed. The IL-6 gene polymorphism was determined in all groups and also compared with 200 healthy controls from a larger study of blood donors. In a multiple regression analysis, adjusted for gender, smoking and age, the effect of CLI was significantly (p < 0.05) associated with elevated levels of the WBC count, hsCRP, proinflammatory cytokines (IL-6, TNFα-R1-2) and endothelial (sICAM, sVCAM) and WBC (CD11b gran) markers. The effect of less advanced PAD (intermittent claudication) was related to an increased concentration of sVCAM-1 and the number of monocytes and granulocytes. DM or leg ulcers were not significantly related to any of the markers. No significant difference in frequency of the various IL-6 genotypes was found between the groups or when compared with the group of 200 blood donors (p > 0.3). Activation of cytokines, endothelial cells and WBC was related to the Fontaine stage of PAD but not to the presence of DM or ulcers. No association was found between the polymorphism in the IL-6 promoter region and PAD.

Keywords

diabetes mellitus inflammation interleukin-6 peripheral arterial disease polymorphism

References

Virchow R. Phloge und Trombose im Gefässystem. Gesammelte Abhandlungen Zur Wissenschaftligen Medizin 1856: 458-63.

Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.

Danielsson P , Schatz P , Swartbol P et al. Response of inflammatory markers to balloon angioplasty in peripheral arterial occlusive disease. Eur J Vasc Endovasc Surg 2000; 20: 550-555.

Fiotti N , Altamura N , Cappelli C , Schillan M , Guarnieri G , Giansante C. Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents. Eur J Vasc Endovasc Surg 2003; 26: 374-380.

Signorelli SS , Mazzarino MC , Di Pino L et al. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med 2003; 8: 15-19.

Mazzone A , De Servi S , Mazzucchelli I et al. Increased expression of CD11b/CD18 on phagocytes in ischaemic disease: a bridge between inflammation and coagulation. Eur J Clin Invest 1997; 27: 648-652.

Menger MD , Vollmar B. Adhesion molecules as determinants of disease: from molecular biology to surgical research. Br J Surg 1996; 83: 588-601.

Ridker PM , Rifai N , Stampfer MJ , Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.

Yudkin JS , Kumari M , Humphries SE , Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214.

10.

Ridker PM , Buring JE , Cook NR , Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.

11.

Fishman D , Faulds G , Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.

12.

Flex A , Gaetani E , Pola R et al. The - 174G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease. Eur J Vasc Endovasc Surg 2002; 24: 264-268.

13.

Jones KG , Brull DJ , Brown LC et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 2260-2265.

14.

Pradhan AD , Manson JE , Rifai N , Buring JE , Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.

15.

Dandona P. Endothelium, inflammation, and diabetes. Curr Diabetes Rep 2002; 2: 311-315.

16.

Dandona P , Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 2002; 90: 27G-33G.

17.

Eriksson KF , Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 1998; 41: 1010-1016.

18.

Miller SA , Dykes DD , Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215-1215.

19.

Ahmadian A , Gharizadeh B , Gustafsson AC et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Biochem 2000; 280: 103-110.

20.

Peter K , Weirich U , Nordt TK , Ruef J , Bode C. Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis. Thromb Haemost 1999; 82 (suppl 1): 38-43.

21.

Brevetti G , Martone VD , de Cristofaro T et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001; 85: 63-66.

22.

Blankenberg S , Barbaux S , Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.

23.

Fiotti N , Giansante C , Ponte E et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999; 145: 51-60.

24.

Cimminiello C. PAD: epidemiology and pathophysiology. Thromb Res 2002; 106: V295-V301.

25.

Pradhan AD , Rifai N , Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 2002; 106: 820-825.

26.

Tsakiris DA , Tschopl M , Jager K , Haefeli WE , Wolf F , Marbet GA. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis 1999; 142: 193-200.

27.

Blann AD , McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-154.

28.

Ridker PM , Cushman M , Stampfer MJ , Tracy RP , Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428.

29.

Peter K , Nawroth P , Conradt C et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997; 17: 505-512.

30.

Dandona P , Aljada A , Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.

31.

Caimi G , Montana M , Ferrara F et al. Polymorphonuclear leukocyte integrin pattern, at baseline and after activation, in type 2 diabetic subjects with macrovascular complications. Acta Diabetol 2003; 40: 14-19.

32.

Aso Y , Okumura K , Yoshida N et al. Plasma interleukin-6 is associated with coagulation in poorly controlled patients with type 2 diabetes. Diabet Med 2003; 20: 930-934.

33.

Aggarwal A , Schneider DJ , Sobel BE , Dauerman HL. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 2003; 92: 924-929.

34.

Hsueh WA , Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92: 10J-17J.

35.

Lam HC. Role of endothelin in diabetic vascular complications. Endocrine 2001; 14: 277-284.

36.

Matsunaga T , Nakajima T , Miyazaki T et al. Glycated high-density lipoprotein regulates reactive oxygen species and reactive nitrogen species in endothelial cells. Metabolism 2003; 52: 42-49.